Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.
作者信息
Graetz Dylan, Crews Kristine R, Azzato Elizabeth M, Singh Ravi K, Raimondi Susana, Mason John, Valentine Marcus, Mullighan Charles G, Holland Ashley, Inaba Hiroto, Leventaki Vasiliki
机构信息
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
出版信息
Haematologica. 2019 May;104(5):e218-e221. doi: 10.3324/haematol.2018.215103. Epub 2019 Feb 28.
Abstract
摘要
相似文献
1
Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.间变性淋巴瘤激酶（ALK）阳性间变性大细胞淋巴瘤伴新型伙伴多聚腺苷酸结合蛋白胞质1（PABPC1）的白血病表现，对单药克唑替尼有反应。
Haematologica. 2019 May;104(5):e218-e221. doi: 10.3324/haematol.2018.215103. Epub 2019 Feb 28.
2
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.阻断克唑替尼诱导的 ALK 阳性间变大细胞淋巴瘤中 BCL2 的上调可触发与细胞死亡相关的自噬。
Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966. Epub 2019 Jan 24.
3
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的I/II期研究及克唑替尼用于复发或难治性神经母细胞瘤的I期研究：一项多中心单臂开放标签试验的研究方案
Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184.
4
Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?ALK 阳性间变大细胞淋巴瘤的治疗是否应根据微小残留病灶进行分层？
Pediatr Blood Cancer. 2021 Jun;68(6):e28982. doi: 10.1002/pbc.28982. Epub 2021 Mar 9.
5
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.IL10RA 调节 NPM1-ALK+ 间变大细胞淋巴瘤对克唑替尼的敏感性。
Blood. 2020 Oct 1;136(14):1657-1669. doi: 10.1182/blood.2019003793.
6
Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.一名肺腺癌患者中新型PRKCB-ALK、EML4-ALK双融合的共存及对克唑替尼的反应
J Thorac Oncol. 2019 Dec;14(12):e266-e268. doi: 10.1016/j.jtho.2019.07.021.
7
CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.CUX1-ALK，一种新的 ALK 重排，对非小细胞肺癌的克唑替尼有反应。
J Thorac Oncol. 2018 Nov;13(11):1792-1797. doi: 10.1016/j.jtho.2018.07.008. Epub 2018 Aug 7.
8
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.比较 FISH、IHC 和 NGS 检测 ALK 对预测晚期非小细胞肺癌患者接受克唑替尼治疗获益的影响。
Lung Cancer. 2019 May;131:62-68. doi: 10.1016/j.lungcan.2019.03.018. Epub 2019 Mar 20.
9
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.系统性间变性大细胞淋巴瘤发病机制的研究进展
Br J Haematol. 2015 Mar;168(6):771-83. doi: 10.1111/bjh.13265. Epub 2015 Jan 6.
10
Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).克唑替尼与化疗联合用于复发或难治性间变性淋巴瘤激酶（ALK）阳性间变性大细胞淋巴瘤（ALCL）患者。
Leuk Lymphoma. 2021 Mar;62(3):571-580. doi: 10.1080/10428194.2020.1839658. Epub 2020 Nov 6.
引用本文的文献
1
Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.结外周 T 细胞淋巴瘤的病理生物学：当前认识与未来方向。
Haematologica. 2023 Dec 1;108(12):3227-3243. doi: 10.3324/haematol.2023.282716.
2
Updates in pathobiological aspects of anaplastic large cell lymphoma.间变性大细胞淋巴瘤病理生物学方面的进展
Front Oncol. 2023 Sep 22;13:1241532. doi: 10.3389/fonc.2023.1241532. eCollection 2023.
3
Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman-Report of a Case with 9-Year Survival.年轻女性小细胞碱性磷酸酶阳性间变大细胞淋巴瘤白血病表现——附 9 年生存病例报告。
Medicina (Kaunas). 2023 Sep 8;59(9):1628. doi: 10.3390/medicina59091628.
4
How molecular advances may improve the diagnosis and management of PTCL patients.分子学进展如何改善外周T细胞淋巴瘤（PTCL）患者的诊断与管理。
Front Oncol. 2023 Jun 23;13:1202964. doi: 10.3389/fonc.2023.1202964. eCollection 2023.
5
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.靶向 CCR7-PI3Kγ 克服 ALK 重排淋巴瘤对酪氨酸激酶抑制剂的耐药性。
Sci Transl Med. 2023 Jun 28;15(702):eabo3826. doi: 10.1126/scitranslmed.abo3826.
6
PABPC1--mRNA stability, protein translation and tumorigenesis.PABPC1——信使核糖核酸稳定性、蛋白质翻译与肿瘤发生
Front Oncol. 2022 Dec 1;12:1025291. doi: 10.3389/fonc.2022.1025291. eCollection 2022.
7
A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.PLCB1-PI3K-AKT 信号轴激活 EMT 促进胆管癌进展。
Cancer Res. 2021 Dec 1;81(23):5889-5903. doi: 10.1158/0008-5472.CAN-21-1538. Epub 2021 Sep 27.
本文引用的文献
1
Characterization of the multimeric structure of poly(A)-binding protein on a poly(A) tail.多聚(A)结合蛋白在多聚(A)尾上的多聚体结构的表征。
Sci Rep. 2018 Jan 23;8(1):1455. doi: 10.1038/s41598-018-19659-6.
2
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.克唑替尼靶向间变性淋巴瘤激酶治疗儿童间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤：儿童肿瘤协作组研究
J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.
3
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.具有 RNF213-、ATIC- 和 TPM3-ALK 融合变异的间变性大细胞淋巴瘤伴间变性淋巴瘤激酶阳性，其特征是重排的 ALK 基因拷贝数增加。
Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.
4
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex.间变性大细胞淋巴瘤中涉及真核延伸因子-1复合物亚基EEF1G的新型ALK融合。
Leukemia. 2017 Mar;31(3):743-747. doi: 10.1038/leu.2016.331. Epub 2016 Nov 14.
5
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.克唑替尼停药后ALK阳性淋巴瘤的突然复发。
N Engl J Med. 2016 Jan 7;374(1):95-6. doi: 10.1056/NEJMc1511045.
6
Poly(A)-binding proteins: structure, domain organization, and activity regulation.聚腺苷酸结合蛋白：结构、结构域组织及活性调控
Biochemistry (Mosc). 2013 Dec;78(13):1377-91. doi: 10.1134/S0006297913130014.
7
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.ALK 受体酪氨酸激酶在人类癌症生物学中的作用机制研究。
Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580.
8
Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.儿童间变性大细胞淋巴瘤中形态学和表型特征的预后影响：ALCL99 研究结果。
J Clin Oncol. 2011 Dec 10;29(35):4669-76. doi: 10.1200/JCO.2011.36.5411. Epub 2011 Nov 14.
9
Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.长春新碱治疗高危间变大细胞淋巴瘤患儿和青少年患者的效果：随机 ALCL99-长春新碱试验的结果。
J Clin Oncol. 2010 Sep 1;28(25):3987-93. doi: 10.1200/JCO.2010.28.5999. Epub 2010 Aug 2.
10
Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count.白血病期间变性大细胞淋巴瘤：白细胞计数异常高。
Pathol Int. 2009 May;59(5):345-53. doi: 10.1111/j.1440-1827.2009.02376.x.
Zotero 插件